Highlights•Safe past de-escalation treatments.•Surgery after complete response might be
overtreatment.•Biopsies might diagnose response.In patients with operable early breast …

Triple negative breast cancer (TNBC) continues to be the subtype of breast cancer with the
highest rates of recurrence and mortality. The lack of expression of targetable proteins such …

Background Neoadjuvant systemic therapy (NST) for triple-negative breast cancer and
HER2-positive breast cancer yields a pathological complete response in approximately 60 …

Introduction In patients with positive lymph nodes (cN+) prior to neoadjuvant treatment
(NAT), which convert to a clinically negative axilla (cN0) after treatment, the use of sentinel …

Objective: To determine whether the association between overall survival (OS) and
response to neoadjuvant chemotherapy (NACT) in breast cancer patients varies with tumor …

Background There is an increasing need to develop a more accurate prediction model for
pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) in breast …

Breast cancer is the most frequent cancer in women all over the world. The prognosis is
generally good, with a five-year overall survival rate above 90% for all stages. It is still the …

Background The added value of surgery in breast cancer patients with pathological
complete response (pCR) after neoadjuvant systemic therapy (NST) is uncertain. The …

Background For breast cancer patients undergoing neoadjuvant chemotherapy (NAC),
pathologic complete response (pCR; no invasive or in situ) cannot be assessed non …

Importance Image-guided breast biopsy of a residual imaging abnormality or tumor bed after
neoadjuvant chemotherapy (NACT) is increasingly used to assess residual cancer, facilitate …